Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Status:
Recruiting
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX
plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C
stage hepatocellular carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University